How should terbinafine be used to treat onychomycosis, including appropriate dosing, treatment duration, monitoring requirements, and contraindications?

Terbinafine for Onychomycosis

Terbinafine 250 mg daily should be your first-line treatment for dermatophyte onychomycosis: 6 weeks for fingernails and 12-16 weeks for toenails, with mandatory baseline liver function tests and complete blood count before starting therapy. 1, 2

Why Terbinafine First

Terbinafine demonstrates superior efficacy compared to all alternatives. In a large multicenter trial of 508 patients, continuous terbinafine achieved 55% complete cure versus only 26% with pulsed itraconazole at 72 weeks. More importantly, at 5-year follow-up, mycological cure without retreatment was maintained in 46% of terbinafine patients versus only 13% with itraconazole, with significantly lower relapse rates (23% vs 53%). 1

The drug works through fungicidal action by inhibiting squalene epoxidase, causing both ergosterol depletion and toxic squalene accumulation. This dual mechanism explains its superior long-term outcomes. 1

Dosing Regimen

Standard Continuous Therapy (Preferred)

• Fingernail onychomycosis: 250 mg once daily for 6 weeks 1, 2
• Toenail onychomycosis: 250 mg once daily for 12-16 weeks 1, 2

The continuous regimen is superior to pulse dosing. A 2023 study showed continuous therapy achieved 76.67% clinical cure versus only 26.67% with pulse therapy. 3 While one older study suggested pulse therapy (500 mg daily for 1 week every 4 weeks) might be comparable, the most recent evidence strongly favors continuous dosing. 4, 3

Pre-Treatment Requirements

You must obtain baseline laboratory tests: 1, 2

• Liver function tests (ALT and AST)
• Complete blood count

These are particularly critical in patients with:

• History of heavy alcohol consumption
• Prior hepatitis
• Pre-existing liver disease
• Hematological abnormalities
• Pediatric patients (off-label use)

Confirm diagnosis mycologically before starting treatment - culture and KOH preparation are essential. 2

Monitoring During Treatment

Re-evaluate patients 3-6 months after treatment initiation. The optimal clinical effect appears months after completing therapy due to the time required for healthy nail outgrowth. 1, 2 Terbinafine persists in nails for up to 6 months post-treatment, providing continued antifungal activity. 1

If disease persists at follow-up, additional treatment courses can be given. 1

Absolute Contraindications

• Active or chronic liver disease - rare but serious hepatotoxicity can occur, sometimes requiring liver transplant 1, 2
• History of allergic reaction to oral terbinafine - risk of anaphylaxis 2

Critical Warnings to Discuss With Patients

Patients must immediately report and you must discontinue terbinafine if they develop:

1. Hepatotoxicity signs: persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools 2

2. Taste disturbance: Can be severe, prolonged, or permanent - this is not reversible in all cases 1, 2

3. Smell disturbance: May be prolonged or permanent 2

4. Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome - look for hives, mouth sores, blistering/peeling skin, facial swelling 2

5. Severe neutropenia: Discontinue if neutrophil count ≤1,000 cells/mm³ 2

6. Depressive symptoms: Monitor for new or worsening depression 2

Drug Interactions

Terbinafine has minimal drug interactions compared to azoles, which is a significant advantage. 1 The only clinically significant interaction is with drugs metabolized by cytochrome P450 2D6 (e.g., certain antidepressants, beta-blockers, antiarrhythmics). 1

Special Populations

• Pregnancy: Not recommended - unknown fetal risk. Onychomycosis treatment should be deferred until after pregnancy. 2
• Breastfeeding: Terbinafine passes into breast milk - discuss risks/benefits 2
• Renal/hepatic impairment: Clearance is decreased; dose adjustment may be needed 1
• Children: Not FDA-approved for pediatric onychomycosis, but used off-label with weight-based dosing (requires baseline monitoring) 1

When to Consider Alternatives

Use itraconazole as second-line if:

• Terbinafine is contraindicated
• Patient cannot tolerate terbinafine
• Candida onychomycosis is confirmed (terbinafine has lower activity against Candida) 1

Use fluconazole 450 mg weekly for 6-12 months if:

• Both terbinafine and itraconazole are not tolerated
• Compliance concerns favor once-weekly dosing
• Candida infection is present 1

Common Pitfalls to Avoid

1. Starting treatment without mycological confirmation - always confirm diagnosis first
2. Skipping baseline liver function tests - this is mandatory, not optional
3. Not warning about permanent taste/smell loss - patients must understand this risk upfront
4. Inadequate treatment duration - full 12-16 weeks needed for toenails, not shorter courses
5. Expecting immediate results - healthy nail growth takes months after treatment completion
6. Using in active liver disease - this is an absolute contraindication

The evidence strongly supports terbinafine as superior to all alternatives for dermatophyte onychomycosis based on higher cure rates, lower relapse rates, better tolerability, and fewer drug interactions. 1, 5